Introduction {#Sec1}
============

Hypoxic ischaemic encephalopathy (HIE) is the most common cause of disability and death after out-of-hospital cardiac arrest (OHCA) \[[@CR1], [@CR2]\]. The developing neurological damage is initially related to an ischaemia--reperfusion injury and reactive oxygen species (ROS), which may increase the oxidative damage to the brain \[[@CR3]\]. This is followed by cerebral hypoperfusion, possibly caused by increased vasoconstriction during the first 72 h of post-resuscitation care, further aggravating the developing HIE \[[@CR4]\]. Previous studies have suggested a decrease in cerebral blood flow and an increase in oxygen extraction in cardiac arrest patients \[[@CR5]\].

Arterial carbon dioxide tension (PaCO~2~) is a major determinant of cerebral blood flow (CBF) \[[@CR6]\]. In experimental studies, carbon dioxide seems to have anticonvulsive \[[@CR7]\], anti-inflammatory and antioxidant properties \[[@CR8]\], suggesting a protective role of PaCO~2~ in the development of HIE. According to a recent meta-analysis of observational data, both hypocapnia and hypercapnia are associated with poor outcomes after cardiac arrest \[[@CR9]\]. One randomised controlled trial with 83 patients found, on the contrary, that targeting mild hypercapnia (6.7--7.3 kPa) after cardiac arrest attenuated the increase of neuron-specific enolase (NSE) concentrations over time, suggesting a possible protective effect of mild hypercapnia against neurological injury \[[@CR10]\]. Concerns related to higher PaCO~2~ levels include increased cerebral oedema, respiratory acidosis and impaired right ventricular function, which may all contribute to poor outcomes \[[@CR11]--[@CR13]\].

Regarding oxygen, experimental studies have shown that exposure to very high levels of arterial oxygen tension (PaO~2~) during post-resuscitation care may increase ROS production and exacerbate the developing neurological damage \[[@CR14]\]. Indeed, in retrospective and observational human studies, severe hyperoxia (PaO~2~ \> 40 kPa) has been associated with poor outcome after cardiac arrest \[[@CR15]--[@CR19]\]. In contrast, moderate hyperoxia during post-resuscitation intensive care has been associated with better long-term neurological recovery and improved organ function \[[@CR20]\]. A retrospective analysis from one large intensive care unit (ICU) registry suggested that the PaO~2~ associated with the lowest mortality was around 20 kPa \[[@CR21]\].

In mechanically ventilated patients, both PaCO~2~ and PaO~2~ can be altered via the ventilator settings \[[@CR22]\]. Currently there are limited high-quality data on the optimal carbon dioxide and oxygen targets in cardiac arrest patients. Accordingly, we performed a multicentre, randomised pilot trial to assess the feasibility and the effect on the serum concentration of NSE of targeting low-normal or high-normal PaCO~2~ and normoxia or moderate hyperoxia after OHCA and successful resuscitation. In addition, we investigated the effect of these interventions on other markers of neurological and cardiac injury, electroencephalography (EEG) and cerebral oxygenation. Our hypothesis was that targeting high-normal PaCO~2~ and moderate hyperoxia would result in lower NSE concentrations at 48 h after cardiac arrest.

Methods {#Sec2}
=======

Trial design {#Sec3}
------------

The full details of the Carbon dioxide, Oxygen and Mean arterial pressure After Cardiac Arrest and REsuscitation (COMACARE) study have been previously described \[[@CR23]\]. In brief, we conducted a prospective, multicentre, randomised trial with a 2^3^ factorial design. A total of 123 unconscious, mechanically ventilated patients resuscitated from OHCA were randomly assigned to intervention targets of low-normal or high-normal PaCO~2~, normoxia or moderate hyperoxia and low-normal or high-normal mean arterial pressure (MAP) for the first 36 h in the intensive care unit (ICU). Each patient was randomised into one of eight arms with each arm having a different combination of targets for PaCO~2~, PaO~2~ and MAP. In this paper we report the results of the low-normal vs. high-normal PaCO~2~ and the normoxia vs. moderate hyperoxia comparisons.

Participants {#Sec4}
------------

We included adult patients resuscitated from witnessed OHCA of presumed cardiac origin with ventricular fibrillation (VF) or ventricular tachycardia (VT) as the initial rhythm. For details regarding the inclusion and exclusion criteria, the participating centres, the informed consent and the ethical approval, please see the electronic supplemental material (ESM).

Interventions {#Sec5}
-------------

After ICU admission and randomisation, we directed the treating personnel to target low-normal (4.5--4.7 kPa) or high-normal (5.8--6.0 kPa) PaCO~2~ by adjusting the minute ventilation (tidal volume and ventilation rate) delivered by the ventilator. Normoxia (10--15 kPa) or moderate hyperoxia (20--25 kPa) were targeted by adjusting FiO~2~ and PEEP levels on the ventilator. Laminated signs designating the intervention targets were used at the patients' bedsides and on the ventilators. The ventilator adjustments were guided by arterial blood gas (ABG) analyses (corrected to each patient's actual temperature) performed at least every 3 h. We used end-tidal carbon dioxide (EtCO~2~) value as an additional guide in targeting the desired PaCO~2~ level. In the normoxia group, we used peripheral oxygen saturation (SpO~2~) as an additional guide, targeting an SpO~2~ value of 95--98%. A volume-controlled or a pressure-controlled ventilation mode was used according to the treating clinician's preference. We continued the intervention for 36 h from the ICU admission or until the patient was extubated or ventilation was set to a spontaneous mode, whichever occurred first. All patients received targeted temperature management (TTM) at 33 °C or 36 °C and were sedated according to the treating clinicians' instructions. All patients received standard care, monitoring and assessments based on the protocol of the ICU, including direct blood pressure monitoring via an arterial catheter.

Outcomes {#Sec6}
--------

The primary outcome was the NSE serum concentration at 48 h after cardiac arrest. The main feasibility outcomes were the differences in PaCO~2~ and PaO~2~ between the groups targeting low-normal (4.5--4.7 kPa) and high-normal (5.8--6.0 kPa) PaCO~2~ and normoxia (10--15 kPa) and moderate hyperoxia (20--25 kPa), respectively. The prespecified secondary outcomes were NSE serum concentrations at 24 and 72 h after cardiac arrest; S100B protein (a biomarker of glial injury) serum concentrations at 24, 48 and 72 h after cardiac arrest; cardiac troponin (TnT) plasma concentrations at 24, 48 and 72 h after cardiac arrest; regional frontal cerebral oxygenation (rSO~2~) measured by continuous near-infrared spectroscopy (NIRS) monitoring during the first 48 h after admission to the ICU; results of continuous EEG monitoring for the first 48 h after admission to the ICU interpreted by an experienced senior neurophysiologist blinded to study group allocation; neurological recovery assessed with Cerebral Performance Category (CPC) at 6 months after cardiac arrest (CPC 1--2 considered a good outcome, and CPC 3--5 a poor outcome) determined by an experienced neurologist blinded to study group allocation; total duration of intensive care; total duration of mechanical ventilation; length of hospital stay; discharge destination and vital status at 30 days after cardiac arrest (dead or alive). Other feasibility outcomes included distribution of values for primary and secondary outcomes, randomised/screened patient ratio, consent rate, data completion rate and recruitment duration. The predefined serious adverse events (SAE) that could be related to the interventions were severe hypercapnia and respiratory acidosis (PaCO~2~ \> 10 kPa and pH \< 7.15), unexplained brain oedema on CT scanning and severe ARDS (PaO~2~/FiO~2~ ratio of \< 100 mmHg).

Data collection, randomisation and statistical methods {#Sec7}
------------------------------------------------------

The data collection and laboratory methods, randomisation procedure and statistical analysis are described in detail in the ESM.

Results {#Sec8}
=======

For the flowcharts demonstrating patient enrolment and group allocations, please see the ESM (Fig. 1a,b). The first patient was randomised on 22 March 2016, and recruitment was completed by 3 November 2017. The 6-month follow-up of the last patient was completed by 3 May 2018. The baseline characteristics and resuscitation factors were comparable between the groups (Table [1](#Tab1){ref-type="table"}). We observed a clear separation during the intervention in PaCO~2~ between the low-normal and the high-normal PaCO~2~ groups and in PaO~2~ between the normoxia and the moderate hyperoxia groups (Fig. [1](#Fig1){ref-type="fig"}). The median (interquartile range \[IQR\]) expiratory tidal volume per body weight and the median (IQR) ventilation rate were 5.8 ml/kg (5.2--6.8 ml/kg) and 12 min^−1^ (12--14 min^−1^) in the low-normal PaCO~2~ group and 5.4 ml/kg (4.8--5.9 ml/kg) and 11 min^−1^ (10--12 min^−1^) in the high-normal PaCO~2~ group, respectively. The median (IQR) FiO~2~ and PEEP levels were 35% (30--40%) and 7.2 cmH~2~O (6.2--8.2 cmH~2~O) in the normoxia group and 50% (45--59%) and 8.2 cmH~2~O (6.3--10.0 cmH~2~O) in the moderate hyperoxia group, respectively.Table 1Baseline characteristics of the study populationLow-normal PaCO~2~ group (*n* = 61)High-normal PaCO~2~ group (*n* = 59)Normoxia group (*n* = 61)Moderate hyperoxia group (*n* = 59)Demographic characteristics Age, mean ± SD, years58 ± 1161 ± 1559 ± 1360 ± 14 Male sex, *n* (%)53 (87)45 (76)50 (82)48 (81) Weight, mean ± SD, kg86 ± 1783 ± 1683 ± 1586 ± 18Neurologic function before cardiac arrest Normal, CPC score 1, *n* (%)56 (92)55 (93)56 (92)55 (93) Some disability, CPC core 2, *n* (%)5 (8)4 (7)5 (8)4 (7)Medical history Antihypertensive medication, *n* (%)27 (44)33 (56)31 (51)29 (49) Chronic heart failure (NYHA class IV), *n* (%)^a^2 (3)02 (3)0 (0) Inhaled corticosteroids, *n* (%)1 (2)5 (8)5 (8)1 (2) Inhaled bronchodilators, *n* (%)2 (3)6 (10)5 (8)3 (5) Smoker, *n* (%)^b^25 (41)15 (25)19 (31)21 (36)Cardiac arrest location Home, *n* (%)34 (56)26 (44)33 (54)27 (46) Public place, *n* (%)27 (44)33 (56)28 (46)32 (54)Resuscitation factors Bystander-initiated resuscitation, *n* (%)50 (82)48 (81)50 (82)48 (81) Time to basic life support^c^, median (IQR), min7 (5--9)8 (6--10)7 (6--10)7 (6--9) Time to advanced life support, median (IQR), min9 (7--12)10 (8--13)10 (8--12)10 (7--12) Time to ROSC, median (IQR), min20 (16--25)21 (17--26)20 (16--25)21 (16--27) Intubated during resuscitation, *n* (%)30 (49)27 (46)28 (46)29 (49)Immediate interventional cardiology Prehospital thrombolysis, *n* (%)2 (3)2 (3)2 (3)2 (3) Coronary angiography before ICU admission, *n* (%)31 (51)32 (54)35 (57)28 (47)Clinical status on ICU admission GCS after ROSC, median (IQR)^d^3 (3--3)3 (3--3)3 (3--3)3 (3--3) APACHE II score, median (IQR)27 (24--30)29 (25--33)27 (24--31)28 (25--31) Prehospital cooling, *n* (%)5 (8)5 (8)3 (5)7 (12) Dose of norepinephrine, mean ± SD, µg/kg/min0.07 ± 0.10.07 ± 0.10.07 ± 0.10.07 ± 0.1 Time from ROSC to randomisation, median (IQR), min159 (130--204)180 (143--216)178 (139--216)166 (135--192)Targeted temperature management 33 °C, *n* (%)43 (70)40 (68)41 (67)42 (71) 36 °C, *n* (%)18 (30)19 (32)20 (33)17 (29)*PaCO*~*2*~ arterial carbon dioxide tension, *SD* standard deviation, *IQR* interquartile range, *CPC* Cerebral Performance Category \[1, good cerebral performance (normal life); 2, moderate cerebral disability (disabled but independent); 3, severe cerebral disability (conscious but disabled and dependent); 4, coma or vegetative state (unconscious); 5, brain death\], *NYHA* New York Heart Association, *CPR* cardiopulmonary resuscitation, *ICU* intensive care unit, *GCS* Glasgow coma scale, *ROSC* return of spontaneous circulation, *APACHE* acute physiology and chronic health evaluation^a^Data missing for 2 patients^b^Data missing for 13 patients^c^The time for a paramedic unit with BLS equipment and skills to reach the patient^d^Data missing for 9 patients Fig. 1Median (interquartile range) **a** PaCO~2~ during the intervention in the low-normal and high-normal PaCO~2~ groups. **b** PaO~2~ during the intervention in the normoxia and moderate hyperoxia groups

We did not find significant differences in the median serum NSE concentration at 48 h after cardiac arrest between the intervention groups (in the low-normal PaCO~2~ group, 18.8 µg/l \[IQR 13.9--28.3 µg/l\] and in the high-normal PaCO~2~ group, 22.5 µg/l \[IQR 14.2--34.9 µg/l\], *p* = 0.400; in the normoxia group, 22.3 µg/l \[IQR, 14.8--27.8 µg/l\] and in the moderate hyperoxia group, 20.6 µg/l \[IQR, 14.2--34.9 µg/l\], *p* = 0.594). The NSE, S100B and TnT concentrations were also comparable over time in the low-normal PaCO~2~ and high-normal PaCO~2~ groups and the normoxia and moderate hyperoxia groups (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}). Fig. 2Baseline, 24 h, 48 h and 72 h median (interquartile range) serum neuron-specific enolase (NSE) concentrations for patients allocated to targeting **a** low-normal and high-normal PaCO~2~, **b** normoxia and moderate hyperoxia Fig. 3Baseline, 24 h, 48 h and 72 h median (interquartile range) serum S100B concentrations for patients allocated to targeting **a** low-normal and high-normal PaCO~2~, **b** normoxia and moderate hyperoxia Fig. 4Baseline, 24 h, 48 h and 72 h median (interquartile range) plasma cardiac troponin (TnT) concentrations for patients allocated to targeting **a** low-normal and high-normal PaCO~2~, **b** normoxia and moderate hyperoxiaFig. 5Median (interquartile range) regional cerebral oxygen saturation (rSO~2~) during the intervention in the **a** low-normal and high-normal PaCO~2~ groups. **b** normoxia and moderate hyperoxia groups

The median cerebral oxygen saturation (rSO~2~) was significantly higher in the high-normal PaCO~2~ group than in the low-normal PaCO~2~ group, *p* \< 0.001 (Fig. [5](#Fig5){ref-type="fig"}a). In addition, the rSO~2~ was significantly higher in the moderate hyperoxia group than in the normoxia group, *p* \< 0.001 (Fig. [5](#Fig5){ref-type="fig"}b). We found no significant differences between any of the groups regarding mortality at 30 days after cardiac arrest, good neurological recovery (CPC 1--2) at 6 months after cardiac arrest, the duration of intensive care or mechanical ventilation, or the frequency of the predefined SAEs (Table [2](#Tab2){ref-type="table"}). The EEG grading at the ICU admission and the end of the intervention was also similar in all groups (Table [3](#Tab3){ref-type="table"}). Regarding the NSE results at 48 h after cardiac arrest or good neurological outcomes at 6 months, we did not find any significant interactions between the PaCO~2~, PaO~2~, MAP or TTM targets (ESM Table 4). Table 2Primary and secondary outcomes after the interventionLow-normal PaCO~2~ group (*n* = 61)High-normal PaCO~2~ group (*n* = 59)*P* valueNormoxia group (*n* = 61)Moderate hyperoxia group (*n* = 59)*P* valuePrimary outcome Median (IQR) NSE at 48 h after cardiac arrest, µg/l^a^18.8 (13.9--28.3)22.6 (14.8--34.9)0.29022.4 (14.8--28.3)20.6 (14.2--34.9)0.649Secondary outcomes Neurologic recovery at 6 months after cardiac arrest  Good, CPC score 1--2, *n* (%)43 (71)35 (59)0.20042 (69)36 (61)0.368 Mortality 30 days after cardiac arrest, *n* (%)15 (25)23 (39)0.09018 (30)20 (34)0.605 Median (IQR) duration of intensive care, h^b^92 (66--136)104 (79--147)0.12097 (73--140)100 (76--143)0.810 Median (IQR) duration of mechanical ventilation, h^c^63 (47--97)75 (52--110)0.58961 (47--95)74 (52--115)0.211Severe adverse events Severe hypercapnia and respiratory acidosis (PaCO~2~ \> 10 kPa and pH \< 7.15), *n* (%)0 (0)1 (2)0.3071 (2)0 (0)0.323 Unexplained brain oedema on CT scanning, *n* (%)0 (0)1 (2)0.3071 (2)0 (0)0.323 Severe ARDS (PaO~2~/FiO~2~ \< 100 mmHg), *n* (%)0 (0)2 (3)0.1471 (2)1 (2)0.981*PaCO*~*2*~ arterial carbon dioxide tension, *IQR* interquartile range, *NSE* neuron-specific enolase, *CPC* cerebral performance category \[1, good cerebral performance (normal life); 2, moderate cerebral disability (disabled but independent); 3, severe cerebral disability (conscious but disabled and dependent); 4, coma or vegetative state (unconscious); 5, brain death\], *CT* computed tomography, *ARDS* acute respiratory distress syndrome, *FiO*~*2*~ fraction of inspired oxygen^a^Data missing for 1 patient^b^Data missing for 6 patients^c^Data missing for 3 patients Table 3EEG grading in the low-normal and high normal PaCO~2~ groups at ICU admission and at the end of the interventionEEG grade^a^ICU admissionEnd of interventionLow-normal PaCO~2~High-normal PaCO~2~NormoxiaModerate hyperoxiaLow-normal\
PaCO~2~High-normal\
PaCO~2~NormoxiaModerate hyperoxia 117 (29)14 (24)19 (32)12 (20)43 (73)35 (59)43 (73)35 (59) 23 (5)2 (3)1 (2)4 (7)3 (5)4 (7)4 (7)3 (5) 339 (66)43 (73)39 (66)43 (73)13 (22)20 (34)12 (20)21 (36)*p* = 0.710*p* = 0.167*p* = 0.294*p* = 0.181Data are presented as *n* (%) of patients*EEG* electroencephalography, *PaCO*~*2*~ arterial carbon dioxide tension, *ICU* intensive care unit^a^EEG grading system for continuous EEG findings following cardiac arrest according to Crepeau et al.: mild (grade 1), moderate (grade 2) and severe (grade 3)

Discussion {#Sec9}
==========

In this prospective, randomised trial, we found that targeting a specific level of PaCO~2~ or PaO~2~ was feasible in comatose, mechanically ventilated patients after cardiac arrest. However, these interventions did not change the concentration of NSE at 48 h after cardiac arrest or any of the measured markers of neurological or cardiac injury. Targeting high-normal PaCO~2~ or moderate hyperoxia both increased cerebral oxygenation measured by NIRS, but the implications of this are unclear. The preliminary results of the current trial cannot confirm or refute a benefit or harm within the studied carbon dioxide and oxygen ranges.

We chose to use two markers of cerebral injury in this trial. NSE is a cytoplasmic glycolytic enzyme found in neurons and neuroectodermal cells, and S100B is a protein specific to neuroglial cells. Both are released into the cerebrospinal fluid and bloodstream after neuronal damage, and their concentrations during the first 24--72 h after cardiac arrest correlate with the severity of the brain injury and the probability of a poor outcome \[[@CR24]--[@CR27]\]. We chose the NSE concentration at 48 h as the primary outcome because it is well documented as a surrogate marker of HIE and it has an established role in the multimodal prognostication of the OHCA patients \[[@CR28]\]. The similar levels of these surrogate markers in all intervention groups of our study suggest that targeting higher or lower PaCO~2~ within the normal range or moderately elevated PaO~2~ instead of normoxia does not markedly affect the development of HIE in post cardiac arrest patients. Compared to previous trials \[[@CR10], [@CR29]\], the NSE concentrations in our study were lower and already decreasing at 48 h after cardiac arrest. This is likely explained by our relatively strict inclusion criteria.

It is thought that the development of the HIE begins early after the ROSC and for this reason the interventions aiming at affecting its course should be started as early as possible. For practical reasons, targeting specific levels of PaCO~2~ and PaO~2~ is difficult during prehospital care. Thus, we decided to start the interventions immediately after ICU admission at the hospital. Moreover, we think that the delay between the ROSC and the beginning of the interventions was acceptable for most participants (Table [1](#Tab1){ref-type="table"}). However, it is possible that the potential effect of the interventions was decreased as a result of the delay.

This trial was not powered for mortality or neurologic outcome and the results based on a surrogate marker of brain injury cannot exclude benefits or harms from different levels of PaCO~2~ within the normal range or moderate hyperoxia after cardiac arrest. The results of our study support the safety and feasibility of studying the effects of these interventions in a larger trial. However, because the NSE results were so similar between the intervention groups, it might be more worthwhile to look into the effect of different levels of PaCO~2~ and PaO~2~ instead. A larger randomised trial comparing mild hypercapnia (6.7--7.3 kPa) with normocapnia is already taking place (NCT03114033). There is an imminent need for large trials on the long-term effects of different oxygen targets in patients after cardiac arrest and other forms of neurocritical illness \[[@CR30]\].

The effect of PaCO~2~ may differ according to the target temperature during TTM, and hypocapnia may be especially common in patients treated with a target temperature of 33 °C \[[@CR31]\]. Cerebrovascular reactivity is maintained during therapeutic hypothermia, and hypocapnia may cause decreased cerebral blood flow and ischaemia in these patients. Regarding oxygen, in the only randomised study performed on the use of oxygen in cardiac arrest patients, an increase in NSE within a subgroup of patients exposed to 100% oxygen and not treated with TTM at 33 °C was seen \[[@CR32]\]. This may indicate harmful effects of extreme hyperoxia on the developing HIE especially in patients without the attenuating effect of hypothermia. Indeed, the results of one large registry study suggested no association between oxygen and survival in OHCA patients predominantly treated with hypothermia \[[@CR17]\]. We, however, included patients treated with TTM targets of both 33 °C and 36 °C and found no interaction between temperature and neither carbon dioxide nor oxygen targets.

We found that high-normal PaCO~2~ and moderate hyperoxia resulted in higher cerebral oxygen saturation when compared with low-normal PaCO~2~ and normoxia, respectively. Higher rSO~2~ may reflect improved oxygen delivery, and there are some data suggesting that higher rSO~2~ is related to better outcome after cardiac arrest \[[@CR33]\]. Recently, Taccone and colleagues showed a moderate relationship between cerebral perfusion pressure and rSO~2~ in OHCA patients undergoing TTM \[[@CR34]\]. Nevertheless, the relationship between rSO~2~, CBF and outcome is not fully understood. Combining continuous transcranial Doppler ultrasound with NIRS would likely have provided additional information of the CBF. However, for practical reasons, it was not possible to implement in this multicentre trial.

In experimental studies, CO~2~ has exhibited potent anticonvulsive properties \[[@CR7]\]. In patients with subarachnoid haemorrhage, there appears to be an association between invasively measured low levels of oxygen in brain tissue and periodical epileptic discharges \[[@CR35]\]. In this pilot trial, we did not find any association between the targeted carbon dioxide or oxygen level and EEG abnormalities. Considering the relatively small absolute difference in PaCO~2~ between the groups, this study may not have been powered to exclude an anticonvulsive effect of high-normal PaCO~2~ or different oxygen levels.

Cardiac arrest and resuscitation result in global ischaemia--reperfusion injury which affects the heart and may lead to myocardial stunning and haemodynamic instability \[[@CR36]\]. Moreover, this myocardial ischaemia--reperfusion damage may be aggravated by myocardial infarction because acute coronary syndrome (ACS) is the most common cause of OHCA. Hypercapnia has been related to impaired right ventricular function and acidosis which may negatively affect the recovery of critically ill neurologic patients \[[@CR12]\]. The results of two large trials investigating the effect of hyperoxia on myocardial injury in ACS patients were controversial \[[@CR37], [@CR38]\]. There are no previous data from randomised trials on the effect of different levels of PaCO~2~ or moderate hyperoxia on myocardial damage after cardiac arrest and resuscitation. We found that the concentration of TnT was comparable in the two PaCO~2~ groups as well as in the two PaO~2~ groups during the first 72 h after cardiac arrest.

Our trial has several strengths. First, the study protocol, including the plan for the statistical analysis, had been previously published \[[@CR23]\]. Second, by using relatively strict eligibility criteria, the study was focused on a homogenous group of OHCA patients, thereby reducing the bias caused by differences in baseline characteristics and resuscitation factors. Third, we carried out post-resuscitation intensive care according to the current guidelines for all patients. Fourth, we studied patients in multiple centres in two countries. Fifth, we took frequent ABG samples and used continuous EtCO~2~ and SpO~2~ monitoring to ensure that PaCO~2~ and PaO~2~ remained at the target level for the whole intervention period. Finally, we recorded frontal rSO~2~ and EEG continuously during the whole intervention.

This study also has some limitations. First, although we conducted a multicentre trial, most participants were recruited at one hospital. Second, because the PaCO~2~, PaO~2~, EtCO~2~ and SpO~2~ are routinely monitored variables in the ICU, the study intervention could not be blinded; thus, the treating personnel were aware of the study group allocations. Third, we used a four-channel technique for EEG monitoring. There is a risk that some focal epileptic discharges may have been undetected. Finally, the blood samples taken at the Danish site had to be analysed on-site for logistical reasons. However, to minimise a possible bias resulting from technical issues, the same laboratory kits for NSE and S100B evaluation were used in both Finland and Denmark.

Conclusions {#Sec10}
===========

Targeting low-normal or high-normal PaCO~2~ and normoxia or moderate hyperoxia was feasible in comatose mechanically ventilated patients admitted to the ICU after OHCA and resuscitation. The target levels of PaCO~2~ or PaO~2~ did not affect the serum concentration of NSE at 48 h. High-normal PaCO~2~ and moderate hyperoxia resulted in better cerebral oxygen saturation which may indicate higher CBF and oxygen delivery, but the clinical implications of these findings are unclear.

Other information {#Sec11}
=================

Protocol {#Sec12}
--------

The protocol of the COMACARE study has been previously published \[[@CR23]\].
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 {#Sec13}
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